Biohaven Therapeutics Ltd.

Bristol-myers Squibb Compnay

Yale University

Celldex Therapeutics Limited

Cenestra LLC

Biohaven Pharmaceutical Ireland Dac

Biohaven Pharmaceutical Holding Company Limited

Pfizer Ireland Pharmaceuticals Unlimited Company

Vladimir Coric

Robert Berman

Tibor P Keler

John H Krystal

Gerard Sanacora

Thomas Davis

Irfan Qureshi

Ronald S Vladyka

Danny Yu

Amgad Saleh

Melissa Beiner

Gilbert L'Italien

Robert Croop

Robert M Berman

Ronald Samuel Vladyka

Gilbert L'ITALIEN

Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions and kits including the immunotherapeutic agents and glutamate modulating agents are also disclosed.

Use of glutamate modulating agents with immunotherapies to treat cancer

Disclosed are methods of treating a disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof, in the form of an oral solid molded fast-dispersing dosage form. Pharmaceutical compositions and kits are also disclosed.

Use of riluzole oral disintegrating tablets for treating diseases

Disclosed are methods of treating Alzheimer's Disease by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.

Use of riluzole prodrugs to treat Alzheimer's disease

Use of riluzole prodrugs to treat alzheimer's disease

Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

Sublingual formulation of riluzole

Disclosed are methods of treating ataxia by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.

Use of riluzole prodrugs to treat ataxias

This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.

Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.

Glutamate agents in the treatment of mental disorders

Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions including the immunotherapeutic agents and glutamate modulating agents are also disclosed.

Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers

Disclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions and instructions are also disclosed.

Rimegepant for CGRP related disorders

This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.

Growing community of inventors

Madison, CT, United States of America

Vladimir Coric